期刊文献+

肾小管上皮间质转化的研究进展 被引量:2

Research progress of renal tubular epithelial-to-mesenchymal transition
原文传递
导出
摘要 肾间质纤维化(renal interstitial fibrosis,RIF)是所有慢性肾脏病发展为终末期肾病的共同通路。RIF的发病机制复杂,目前尚不完全清楚。研究发现肾小管上皮间质转化(epithelial-to-mesenchymal transition,EMT)在RIF的发病机制中起重要作用。抑制或逆转肾小管EMT有助于延缓RIF的发生及发展。该文主要对肾小管EMT的发生机制及药物治疗的研究概况作一综述。 Renal interstitial fibrosis represents the final common pathway of all chronic disease. The mechanism of renal interstitial fibrosis is very complex. It is not entirely clear now. The study found that epithelial-to-mesenchymal transition plays an important role in the renal interstitial fibrosis. Inhibition of epithelial-to- mesenchymal transition may help to slow down the development and progression of renal interstitial fibrosis. The article mainly reviews the mechanism and treatment of enithelial-to- mesenchymal transition.
作者 于方 姜红
出处 《国际儿科学杂志》 2017年第4期267-269,共3页 International Journal of Pediatrics
基金 教育部高校博士点专项基金(20122104110001) 沈阳市科技计划项目(F16-206-9-44)
关键词 肾小管上皮间质转化 肾间质纤维化 药物治疗 Epithelial-to-mesenchymal transition Renal interstitial fibrosis drug therapy
  • 相关文献

参考文献2

二级参考文献73

  • 1王凤英,卢思广,赵彤,李国民.系膜增生型原发性肾病综合征患儿细胞毒性T淋巴细胞相关抗原4基因多态性、蛋白表达及外周血淋巴细胞凋亡的研究[J].中华儿科杂志,2007,45(8):633-634. 被引量:5
  • 2Lombel RM, Hodson EM, Gipson DS, et al. Kidney disease : im- proving global outcomes.Treatment of steroid-resistant nephrot- ic syndrome in children:new guidelines from KDIGO [J]. Pedi- atr Nephrol, 2013,28 : 409-414.
  • 3Yokota S. Mizoribine: mode of action and effects in clinical use[J]. Pediatr Int,2002,44:196-198.
  • 4Takahara S, Takahashi K, Akiyama T, et al. Randomized com- parative trial of mizoribine versus mycophenolate mofetil in com- bination with tacrolimus for living donor renal transplanta- tion [ ] ]. Clin Exp Nephro|, 2013,17 (6) : 899-904.
  • 5Stypinski D, Obaidi M, Combs M, et al. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male vol- unteers [ J ]. Br J Clin Pharmacol, 2007,63 (4) : 459-468.
  • 6Fuke T, Abe Y, Hibino S, et al. Mizoribine requires individual dosing due to variation of bioavailability [J]. Pediatr Int, 2012, 54(6) : 885-891.
  • 7Picard-Jean F, Bougie , Shuto S, et al. The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme[J]. PLOS ONE,2013,8( 1 ) :54621.
  • 8Mori N, Yokooji T, Kamio Y, et al. Increased intestinal absorp- tion of mizoribine, an immunosuppressive agent, in cholestatic rats [ J ].Pharmazie, 2010,65 (7):457-460.
  • 9Mori N, Shimomukai Y, Yokooji T, et al. Modulation in concen- trative nucleoside transporters mediated intestinal absorption of mizoribine art immunosuppressive agent,in lipopohy saccharide- treated rats[J]. Pharmaeie ,2011,66(3) :207-211.
  • 10Kawasaki Y.Mizoribine : a new approach in the treatment of re- nal disease [ J ]. Clin Dev lmmunol, doi : 10.1155/2009/681482.

共引文献13

同被引文献19

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部